Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial

Olga Brawman‐Mintzer, X. Charlene Tang, Marcel Bizien, Philip D. Harvey, Michael David Horner, David B. Arciniegas, Murray A. Raskind, Lisa Johnson-Greene, Raymond Martineau, Mark B. Hamner,

Journal of Neurotrauma · 2021 · 15 citations · 30 references

Concepts

Abstract

= 0.24). Overall, there were no significant differences in changes for all secondary outcomes between the rivastigmine and placebo groups. The most commonly observed adverse events were application site reactions. This trial provides the largest sample to date of veterans with TBI and post-traumatic memory deficits enrolled in a pharmacological trial. Trial Registration: clinicaltrials.gov Identifier: NCT01670526.

References

30